ClinicalTrials.gg
TerminatedNCT02600351Updated Nov 16, 2018Results posted

Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

A Phase 3 interventional study of LDV/SOF and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Terminated at 42 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to lack of feasibility of enrolling participants, the study was terminated early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 174 studies testing ribavirin in Hepatitis C — none open to participants now, 1 under way, none of them phase 3. Ribavirin · Hepatitis C.

Enrollment
84th of 174
87 · median 78
Started
2015
with 19 others
Phase 3
56 of 174
none open now
Registered
154th of 174
by date
Lead sponsor
15 of 174
Gilead Sciences

Among the 174 studies testing ribavirin in Hepatitis C, this one is the 84th largest by enrollment, is one of 20 that started in 2015, is one of 56 in phase 3, and was the 154th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 174 studies testing ribavirin in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 174 studies testing ribavirin in Hepatitis C as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) for 12 weeks with or without ribavirin (RBV) in participants without cirrhosis, and LDV/SOF FDC for 12 weeks with RBV or LDV/SOF FDC for 24 weeks without RBV in participants with cirrhosis.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

Keywords

  • Hepatitis C Virus (HCV)
  • Ledipasvir/Sofosbuvir
  • Ribavirin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • > 15 IU/mL at screening
  • HCV genotype 1 or 4
  • Chronic HCV infection (≥ 6 months)
  • Prior virologic failure after treatment with SOF in combination with simeprevir (SMV) ± RBV or with RBV ± pegylated interferon (PEG)
  • Cirrhotic and non-cirrhotic as determined by standard methods
  • Male and female individuals of who engage in heterosexual intercourse must agree to use protocol specified method(s) of

Key Exclusion Criteria:

  • Prior exposure to approved or experimental non-structural protein (NS5A) inhibitors
  • Prior exposure to nucleos(t)ide polymerase inhibitors, other than SOF
  • Pregnant or nursing female or male with pregnant female partner
  • Coinfection with or virus
  • Current or prior history of clinical hepatic decompensation
  • Hepatocellular carcinoma or other (with exception of certain resolved skin cancers)
  • Chronic use of systemic agents
  • History of illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    LDV/SOF 12 weeks, without cirrhosis

    LDV/SOF for 12 weeks

    Drug: LDV/SOF

  • Experimental
    LDV/SOF + RBV 12 weeks, without cirrhosis

    LDV/SOF + RBV for 12 weeks

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    LDV/SOF + RBV 12 weeks, with compensated cirrhosis

    LDV/SOF + RBV for 12 weeks

    Drug: LDV/SOF · Drug: RBV

  • Experimental
    LDV/SOF 24 weeks, with compensated cirrhosis

    LDV/SOF for 24 weeks

    Drug: LDV/SOF

Interventions

  • DrugLDV/SOF

    90/400 mg FDC tablet administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugRBV

    Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, \< 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Discontinued From Study Treatment for an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With HCV RNA < the Lower Limit of Quantitation (LLOQ) at 4 and 24 Weeks Posttreatment

    SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.

    Time frame: Posttreatment Weeks 4 and 24

  2. Percentage of Participants With Viral Breakthrough

    Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment.

    Time frame: Up to 24 weeks

  3. Percentage of Participants With Viral Relapse

    Viral relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \<LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

  4. Number of Participants With Emerging Resistance

    The full-length NS3, NS5A, and NS5B coding regions were deep sequenced at pretreatment (baseline) for all participants included in the Full Analysis Set, and at posttreatment for all participants who relapsed.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Apr 11, 2018
Limitations and caveats
Due to lack of feasibility of enrolling participants, the study was terminated early. Although, the non-inferiority tests were performed, the actual sample size was inadequate compared to the planned enrollment of 430 participants.

Participant flow

Participants were enrolled at study sites in the United States (including a site in Puerto Rico), and Canada. The first participant was screened on 11 November 2015. The last study visit occurred on 29 May 2017.

Participant flow — Overall Study
MilestoneLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Started17172627
Completed12172022
Not completed5065
Withdrew: Lack of efficacy3052
Withdrew: Lost to follow-up1000
Withdrew: Randomized but not treated1013

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, \< 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)
percentage of participantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Percentage of Participants With Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)81.3 (54.4 to 96.0)100.0 (80.5 to 100.0)80.0 (59.3 to 93.2)91.7 (73.0 to 99.0)
Statistical analysis
  • LDV/SOF 12 Weeks, Without Cirrhosis vs LDV/SOF + RBV 12 Weeks, Without Cirrhosis · Cochran-Mantel-Haenszel · p = 0.065 · Difference in percentages: -18.8 · 95% CI -40.7 to 3.2
  • LDV/SOF + RBV 12 Weeks, With Compensated Cirrhosis vs LDV/SOF 24 Weeks, With Compensated Cirrhosis · Cochran-Mantel-Haenszel · p = 0.25 · Difference in percentages: -11.7 · 95% CI -32.1 to 8.8
PrimaryPercentage of Participants Who Discontinued From Study Treatment for an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued From Study Treatment for an Adverse Event
percentage of participantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Percentage of Participants Who Discontinued From Study Treatment for an Adverse Event0000
SecondaryPercentage of Participants With HCV RNA < the Lower Limit of Quantitation (LLOQ) at 4 and 24 Weeks Posttreatment

SVR4 and SVR24 were defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.

Time frame:
Posttreatment Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < the Lower Limit of Quantitation (LLOQ) at 4 and 24 Weeks Posttreatment
percentage of participantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
SVR493.8 (69.8 to 99.8)100.0 (80.5 to 100.0)88.0 (68.8 to 97.5)95.8 (78.9 to 99.9)
SVR2481.3 (54.4 to 96.0)100.0 (80.5 to 100.0)80.0 (59.3 to 93.2)91.7 (73.0 to 99.0)
SecondaryPercentage of Participants With Viral Breakthrough

Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Viral Breakthrough
percentage of participantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Percentage of Participants With Viral Breakthrough0000
SecondaryPercentage of Participants With Viral Relapse

Viral relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \<LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Viral Relapse
percentage of participantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Percentage of Participants With Viral Relapse18.8020.08.3
SecondaryNumber of Participants With Emerging Resistance

The full-length NS3, NS5A, and NS5B coding regions were deep sequenced at pretreatment (baseline) for all participants included in the Full Analysis Set, and at posttreatment for all participants who relapsed.

Time frame:
Up to Posttreatment Week 24
Reported as:
Count of participants · Participants
Number of Participants With Emerging Resistance
ParticipantsLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Number of Participants With Emerging Resistance3—52

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDV/SOF 12 Weeks, Without Cirrhosis0/16 (0%)0/16 (0%)11/16 (68.8%)
LDV/SOF + RBV 12 Weeks, Without Cirrhosis0/17 (0%)0/17 (0%)14/17 (82.4%)
LDV/SOF + RBV 12 Weeks, With Compensated Cirrhosis0/25 (0%)0/25 (0%)19/25 (76%)
LDV/SOF 24 Weeks, With Compensated Cirrhosis0/24 (0%)1/24 (4.2%)15/24 (62.5%)
Most frequent serious events
Most frequent serious events
EventLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
Gastrointestinal haemorrhageGastrointestinal disorders0/160/170/251/24
Upper gastrointestinal haemorrhageGastrointestinal disorders0/160/170/251/24
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated Cirrhosis
HeadacheNervous system disorders5/162/179/257/24
FatigueGeneral disorders2/166/177/254/24
InsomniaPsychiatric disorders1/165/173/253/24
RashSkin and subcutaneous tissue disorders1/162/175/252/24
VomitingGastrointestinal disorders3/161/171/251/24
CoughRespiratory, thoracic and mediastinal disorders0/163/172/250/24
Muscle spasmsMusculoskeletal and connective tissue disorders0/160/174/250/24
NauseaGastrointestinal disorders2/161/173/253/24
Dry mouthGastrointestinal disorders0/162/170/250/24
ChillsGeneral disorders0/162/170/252/24

Baseline characteristics

Safety Analysis Set: participants who took at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
Mean58 ± 5.757 ± 5.558 ± 7.860 ± 4.559 ± 6.1
Sex: Female, Male
Sex: Female, Male(Participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
Female646521
Male1013191961
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
American Indian Or Alaska Native00011
Asian01001
Black or African American656320
Other00112
White1011181958
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
Hispanic or Latino234716
Not Hispanic or Latino1414211766
Region of Enrollment
Region of Enrollment(participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
Canada122712
Puerto Rico11013
United States1414231667
IL28b Status
IL28b Status(Participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
CC12014
CT1211161756
TT349622
HCV RNA
HCV RNA(log10 IU/mL)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
Mean6.5 ± 0.456.4 ± 0.486.1 ± 0.596.0 ± 0.896.2 ± 0.67
HCV RNA Category
HCV RNA Category(Participants)LDV/SOF 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, Without CirrhosisLDV/SOF + RBV 12 Weeks, With Compensated CirrhosisLDV/SOF 24 Weeks, With Compensated CirrhosisTotal
< 800,000 IU/mL147820
≥ 800,000 IU/mL1513181662
08

Study locations

42 sites
  • Little Rock, Arkansas 72205, United States
  • Los Angeles, California 90027, United States
  • Pasadena, California 91105, United States
  • Rialto, California 92377, United States
  • Sacramento, California 95817, United States
  • Ventura, California 93003, United States
  • New Haven, Connecticut 06520, United States
  • Largo, Florida 33777, United States
  • Weston, Florida 33331, United States
  • Chicago, Illinois 60612, United States
  • Skokie, Illinois 60076, United States
  • Baltimore, Maryland 21202, United States
  • Columbia, Maryland 21045, United States
  • Worcester, Massachusetts 01655, United States
  • Saint Paul, Minnesota 55114, United States
  • Kansas City, Missouri 64131, United States
  • Saint Louis, Missouri 63110, United States
  • Egg Harbor Township, New Jersey 08234, United States
  • Bronx, New York 10467, United States
  • New York, New York 10025, United States
  • New York, New York 10032, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28204, United States
  • Durham, North Carolina 27710, United States
  • Cleveland, Ohio 44109, United States
  • Columbus, Ohio 43212, United States
  • Philadelphia, Pennsylvania 19141, United States
  • Memphis, Tennessee 38104, United States
  • Nashville, Tennessee 37232, United States
  • Austin, Texas 78758, United States
  • Dallas, Texas 75203, United States
  • Dallas, Texas 75246, United States
  • Dallas, Texas 75390, United States
  • Houston, Texas 77030, United States
  • Salt Lake City, Utah 84132, United States
  • Charlottesville, Virginia 22908, United States
  • Seattle, Washington 98101, United States
  • Seattle, Washington 98122, United States
  • Vancouver, British Columbia V5Z 1H2, Canada
  • Montreal, Quebec H2L 4P9, Canada
  • Montreal, Quebec H4A 3J1, Canada
  • Ponce, 00716, Puerto Rico
09

References and documents

Publications

  • Tam E, Brown RS, Satapathy S, Shen X, Camus G, Copans A, et al. Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF), with or without Ribavirin (RBV), for Treatment of HCV-mono and HIV/HCV Co-infected Patients Who Have Failed Prior Treatment with Non-NS5A, SOF-based Therapies [Poster THU-265]. The International Liver Congress™ 2017: European Association for the Study of the Liver (EASL); 2017 19-23 April; Amsterdam, the Netherlands.
  • Tam E, Mantry PS, Satapathy SK, Ghali P, Shen X, Han LL, et al. A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF), with or without Ribavirin (RBV), in HCV Infected Subjects Who Have Failed Prior Treatment with Non-NS5A, SOF-based Therapies (RESCUE) [Poster PP0217]. Asian Pacific Association for the Study of the Liver (APASL); 2017 15-19 February; Shanghai, China.
  • Tam E, Brown RS, Satapathy S, Camus G, Copans A, Rossaro L, et al. Ledipasvir/Sofosbuvir ± Ribavirin in HCV and HIV/HCV Prior SOF-based Virologic Failures (RESCUE and ACTG A5348 Studies) [Poster 568LB]. Conference on Retroviruses and Opportunistic Infections (CROI); 2017 13-16 February; Seattle, WA.
  • Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: Findings from two randomized trials. Liver Int. 2018 Jun;38(6):1010-1021. doi: 10.1111/liv.13616. Epub 2017 Dec 5. PubMed 29091342 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Mar 2017, 16 months.

Results were first posted in Apr 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 9, 2015
StartActual
Nov 11, 2015
Primary completionActual
Mar 21, 2017
CompletionActual
May 29, 2017
Results first posted
Apr 11, 2018
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02600351
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 9, 2015
Start date
Nov 11, 2015
Primary completion
Mar 21, 2017
Completion
May 29, 2017
Results posted
Apr 11, 2018
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribavirin

Start the discussion